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Synthesis of a series of iridium(I) complexes of the type 
[(COD)Ir(IMes)(PPh3)]X (X = BF4, OTf, and BArF) has been 
established. Application of these species in mild hydrogen 
isotope exchange processes revealed more efficient catalysis 
and, further, a wider solvent scope when employing larger, 
more weakly coordinating counterions. 
Ionic transition metal complexes play a central role in catalysis and 
organic synthesis. Although it is more common to tune the properties of 
such catalysts via manipulation of the coordinated ligands on the 
transition metal cation, the past two decades have witnessed a 
significant increase in studies of the effects of changing the negatively 
charged counterion.1 In most cases where the counterion plays a 
spectator role, moving to larger, more weakly coordinating counterions 
has evidenced a positive influence on catalyst efficiency across various 
methodologies, with examples spanning palladium,2 rhodium,3 and 
iridium4 catalyses, among others.1a,b Having stated this, there also exist 
some cases in which the ability of the counterion to coordinate to the 
inner sphere of the transition metal cation is essential for overall 
structural stability.5 Furthermore, changing the counterion has also been 
documented to completely alter reaction pathways in both transition 
metal complex synthesis6 and organic synthesis.7 
 Our interest in this field stems from the development of cationic 
iridium(I) N-heterocyclic carbene (NHC)-phosphine complexes for 
pharmaceutically-relevant hydrogen isotope exchange (HIE) 
processes.8,9 To date, we have reported on the development and 
application of several such complexes, all of which bear the 
hexafluorophosphate counterion.8c,9 In this contribution, we report the 
syntheses and application in HIE of complexes 1b-d, counterion 
variations of our flagship catalyst, 1a (Fig. 1).9,10 As has been 
demonstrated by Pfaltz and others in iridium-based catalysis,4 we 
hypothesised that moving to larger counterions, such as tetrakis[3,5- 
bis(trifluoromethyl)phenyl] borate (BArF), would enhance the activity 
 
Fig. 1 HIE catalysts bearing different counterions. 
and longevity of the proposed new Ir species at lower catalyst loadings. 
Furthermore, as wider preparative applications of HIE require catalysts 
operable in a more expansive array of solvent media,8d,9b,11 we theorised 
that the more diffuse counterions would enhance the solvent scope of 
the catalyst beyond that which we have already reported.9 To 
substantiate these proposals, it was necessary to study complexes 
bearing counterions both larger and smaller than for catalyst 1a. 
 We began our studies with the syntheses of novel complexes 1b and 
1c, using the general method shown in Table 1. Starting from the 
chloro-carbene complex, 2,12,13 the choice of silver salt used to the 
abstract the chloride ligand simultaneously delivered the counterion of 
choice (after addition of PPh3). Both complexes were isolated in 
acceptable yields by simple trituration from ethyl acetate.  
 In turning our attention to the synthesis of complex 1d, the lack of a 
commercially available source of AgBArF prompted the search for a 
silver-free synthetic route. In this regard, it was hypothesised that the 
chloro-carbene intermediate, 2, may be circumvented if the parent 
imidazolium salt required to provide the NHC ligand was partnered 
with a large and weakly coordinating counterion such as BArF. Indeed, 
this approach has promising literature precedent relating to iridium 
complexes bearing a chelating carbene-phosphine ligand.14 Accordingly 
and as detailed in Scheme 1, this approach was successfully realised for  
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Table 1 General procedure for the syntheses of complexes 1b and 1c. 
 
Entry X Catalyst % Yield 
1 BF4 1b 80 
2 OTf 1c 69 
 
our monodentate NHC-phosphine ligand combination. Firstly, NHC 
precursor, 4, was synthesised by salt metathesis from 3. Following in-
situ generation of [(COD)Ir(PPh3)Cl] from 5 and PPh3, 4 was added 
followed by base to yield the desired complex, 1d, in good yield, and 
on gram scale. 
 
 Scheme 1 Silver-free synthesis of complex 1d. 
 All novel compounds, 1b-d and 4, were characterised by NMR (1H, 
13C, 31P, 19F, and 11B), IR, melting point, HRMS, and X-ray 
crystallography. Of particular note is the X-ray structure determination 
of complex 1d, which reveals the similar size of the BArF counterion 
relative to the cationic portion of the complex (Fig. 2).¶ 
 To investigate the impact of the series of counterions in iridium-based 
HIE processes, model reactions employing acetophenone, 6, as the 
substrate were undertaken. In particular, the effect of catalyst loading 
on the labelling efficacy of complexes 1a-d was scrutinised. As shown  
 
Fig. 2 Molecular structure of catalyst 1d as determined by X-ray 
crystallography. 
in Scheme 2, the effect of changing the counterion was clearly drawn 
out at the most accessible and commonly applied reaction temperature 
of 25 ºC. As predicted, the relative efficiency of each catalyst increases 
in order of increasing counterion volume.15 Catalysts 1c and 1d, bearing 
the OTf and BArF counterions, respectively, are more active than 
parent catalyst, 1a, and the catalyst bearing the small BF4 counterion, 
1b. Notably, the reactivity of the triflate catalyst, 1c, contrasts with 
observations made by Pfaltz and co-workers during their study on the 
counterion effects in olefin hydrogenation using PHOX-type chelating 
ligands.4b Where these previous studies showed complete shutdown of 
catalytic activity using the triflate species, we have evidenced that both 
triflate and BArF counterions perform equally well (and, indeed, better 
than the parent catalyst, 1a) at 25 °C within HIE processes. 
Presumably, this difference in the effectiveness of triflate across these 
two systems is related to the different orientations of the ancillary 
ligands in the active catalyst forms. For bidentate PHOX ligands, the 
coordinating groups adopt a cis configuration, allowing coordination of 
the dipolar triflate anion to the iridium centre. In catalyst series 1, the 
bulky NHC and phosphine ligands are known to rest trans to one 
another in the active form.9c Therefore, triflate coordination may be 
blocked by the more effective combined steric bulk of a trans NHC-
phosphine system relative to the more open cis-coordinated PHOX 
ligands. 
 
 
Scheme 2 Assessment of counterion effects on catalyst efficiency. 
 Next, we explored the effective solvent scope of catalyst 1 with 
different counterions. Previously, we have identified 2-MeTHF,  
MTBE, and Et2O as viable alternatives to DCM using catalyst 1a.
9b 
Therefore, we compared the applicable solvent scope of 1a versus the 
most non-polar derivative, 1d, across a wider range of solvents than 
previously explored. Using the same reference reaction as shown in 
Scheme 2 (5 mol% catalyst, 25 °C), we screened a series of ethereal, 
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alcoholic, ester, chlorinated, and aromatic solvents. Firstly, we were 
encouraged to note that the more soluble catalyst, 1d, was generally 
superior to parent catalyst, 1a, within HIE for the range of ether and 
carbonate solvents tested (Fig. 3). For dioxane, MTBE, Et2O, and 2-
MeTHF both catalysts were shown to perform equally well, with the 
larger counterion of 1d offering slight improvements to an already 
efficient deuteration system. However, more significant improvements 
were recorded on comparing the activities of 1a and 1d in iPr2O, THF, 
and the recognised green solvents, CPME and dimethyl carbonate.16  
 Alcohol-derived solvents provided a more varied range of reaction 
efficiencies (Fig. 4). Notably, in all cases, catalyst 1d displayed greater 
levels of activity and was more widely applicable than 1a. The most 
significant reactivity from the alcoholic solvents shown was observed 
in the most sterically shielded (and presumably least coordinating) 
alcohol, tAmOH.  
 A similar pattern of reactivity was observed for ester solvents, and 
accompanied with higher overall levels of deuterium incorporation 
(Fig. 4). Again, the combination of catalyst 1d and the most sterically 
encumbered solvent (iPrOAc over EtOAc) proved most effective. 
Chlorinated solvents DCM and DCE evidenced no difference in 
catalysts 1a and 1d, with both producing almost quantitative D-
incorporation. In contrast, a stark difference in deuterium labelling 
 
Fig. 3 Counterion influence on ether and carbonate solvent scope. Results 
are reported as an average of two runs. 
 
 
 
Fig. 4 Counterion influence on alcohol, ester, chlorinated, and aromatic 
solvent scope. Results are reported as an average of two runs. 
efficiency was recorded between 1a and 1d when using toluene as the 
solvent. Again, catalyst 1d was superior to the less soluble catalyst, 1a. 
Finally, it is also worth noting that more polar solvents DMSO and 
DMF were tested under the same reaction conditions with complex 1d, 
however, only very low levels of deuteration in acetophenone were 
detected (see ESI for results). 
 As stated in the introduction, owing to the highly variable solubility 
profile of different drug classes, HIE processes with drug candidates 
require a flexible solvent choice. To explore the potential benefits of 
expanded solvent scope with catalyst 1d over 1a, we next turned our 
attention to the deuterium labelling of drug molecule, Niclosamide, 8. 
Using catalyst 1a or 1d in DCM, similarly moderate to good deuterium 
incorporation was achieved across all four possible labelling sites 
(Table 2, Entries 1 and 2). This is presumed to be due to the relative 
insolubility of 8 in DCM. On moving to 2-MeTHF as an alternative 
solvent (able to fully solubilise all reactants), catalyst 1a showed 
suppressed deuteration in positions a-c, and enhanced deuteration at 
position d (Entry 3).17 Pleasingly and to excellently exemplify the 
effectiveness of the larger anionic counterion, especially with more 
demanding pharmaceutically-related substrates, catalyst 1d in 2-
MeTHF showed improved labelling in all four positions over all other 
conditions tested (Entry 4 versus 1-3). 
Table 2 Improved  deuterium labelling of Niclosamide with 1d.a 
 
Entry Catalyst X Solvent %Da %Db %Dc %Dd 
1 1a PF6  DCM 66 53 41 66 
2 1d BArF DCM 71 57 18 73 
3 1a PF6 2-MeTHF 51 11 4 98 
4 1d BArF 2-MeTHF 97 96 65 96 
a Percent deuteration determined by 1H  NMR. 
 
Conclusions 
In summary, we have reported on the syntheses of three novel 
complexes of the type [(COD)Ir(IMes)(PPh3)]X (X = BF4, OTf, and 
BArF), with the BArF complex having been accessed by a modified 
and more direct preparative process. Application of these complexes as 
catalysts in hydrogen isotope exchange has demonstrated improved 
catalytic activity at lower catalyst loadings in the order X = BArF §
OTf > PF6 > BF4. Relative to the parent complex (1a, X = PF6), 1d (X = 
BArF) possesses a superior solubility profile and applicable solvent 
scope in HIE processes. This is of fundamental importance to the 
delivery of labelled drug candidates for use in absorption, distribution, 
metabolism, excretion, and toxicology (ADMET) studies. Accordingly, 
the complex 1d now provides a catalyst system of wider potential 
applicability and effectiveness, in particular, within pharmaceutical 
settings. Further and in relation to this, the utility of improved solvent 
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scope has been demonstrated through improved global deuterium 
labelling of the drug molecule Niclosamide in 2-MeTHF. Our on-going 
efforts in this area are focused on the further application of optimal 
catalyst, 1d, in labelling processes and to alternative C-H activation 
methodologies beyond HIE. 
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